Your browser doesn't support javascript.
loading
Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature.
Sharif, K; Watad, A; Bragazzi, N L; Asher, E; Abu Much, A; Horowitz, Y; Lidar, M; Shoenfeld, Y; Amital, H.
Afiliação
  • Sharif K; Department of Medicine "B", Sheba Medical Center, Tel-Hashomer, Israel.
  • Watad A; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
  • Bragazzi NL; Department of Medicine "B", Sheba Medical Center, Tel-Hashomer, Israel.
  • Asher E; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
  • Abu Much A; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
  • Horowitz Y; School of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
  • Lidar M; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
  • Shoenfeld Y; The Leviev Heart Center, Sheba Medical Center, Tel-Hashomer, Israel.
  • Amital H; Department of Medicine "B", Sheba Medical Center, Tel-Hashomer, Israel.
J Clin Pharm Ther ; 42(3): 356-362, 2017 Jun.
Article em En | MEDLINE | ID: mdl-28440561
WHAT IS KNOWN AND OBJECTIVES: Rituximab is a chimeric monoclonal anti-CD20 antibody approved for the treatment of some lymphoid malignancies as well as for autoimmune diseases including rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and vasculitis. Generally, rituximab is well tolerated; nevertheless, some patients develop adverse effects including infusion reactions. Albeit rare, these reactions may in some cases be life-threatening conditions. Rituximab cardiovascular side effects include more common effects such as hypertension, oedema and rare cases of arrhythmias and myocardial infarction. CASE SUMMARY: In this article, we report a case of a 58-year-old man with a history of overlap syndrome including RA and limited scleroderma who was treated with rituximab and developed a dramatic ST-elevation myocardial infarction (STEMI) during the drug administration. WHAT IS NEW AND CONCLUSION: This report underlines previous published reports emphasizing the awareness of such an association. This communication also warrants the importance of screening for ischaemic heart disease in selected cases of patients treated with rituximab.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antirreumáticos / Rituximab / Infarto do Miocárdio com Supradesnível do Segmento ST Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antirreumáticos / Rituximab / Infarto do Miocárdio com Supradesnível do Segmento ST Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article